OncoMatch

OncoMatch/Clinical Trials/NCT04789681

Canakinumab for the Prevention of Lung Cancer, the Can-Prevent-Lung Trial

Is NCT04789681 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Canakinumab for lung carcinoma.

Phase 2RecruitingM.D. Anderson Cancer CenterNCT04789681Data as of May 2026

Treatment: CanakinumabThis phase II trial studies the effects of canakinumab in preventing lung cancer in patients who have high-risk pulmonary nodules. Canakinumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Giving canakinumab may prevent the development of lung cancer.

Check if I qualify

Extracted eligibility criteria

Cancer type

Non-Small Cell Lung Carcinoma

Disease stage

Required: Stage I, IA1, IA2, IA3, IB, II, IIA, IIB, III, IIIA, IIIB, IIIC

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Must have received: curative intent therapy

Patients with history of stage I-III non-small cell lung cancer (NSCLC), who have completed treatment with curative intent

Cannot have received: anti-IL1beta

Has received prior therapy with an anti-IL1beta

Lab requirements

Blood counts

ANC ≥ 1500/uL; Platelets ≥ 100,000/uL; Hemoglobin ≥ 9.0 g/dL or ≥ 5.6 mmol/L (without erythropoietin dependency and without packed red blood cell transfusion within last 2 weeks)

Kidney function

Creatinine ≤ 1.5 x ULN OR measured or calculated creatinine clearance (CrCl) ≥ 30 mL/min for participant with creatinine levels > 1.5 x institutional ULN

Liver function

Total bilirubin ≤ 1.5 x ULN OR direct bilirubin ≤ ULN for participants with total bilirubin levels > 1.5 x ULN; AST and ALT ≤ 2.5 x ULN

Absolute neutrophil count (ANC) ≥ 1500/uL ... Platelets ≥ 100 000/uL ... Hemoglobin ≥ 9.0 g/dL or ≥ 5.6 mmol/L ... Creatinine ≤ 1.5 x ULN OR measured or calculated creatinine clearance ... Total bilirubin ≤ 1.5 x ULN OR direct bilirubin ≤ ULN ... AST and ALT ≤ 2.5 x ULN

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • M D Anderson Cancer Center · Houston, Texas

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify